Likewise, VM-26 treatment markedly increased the cleavage of caspase-3 and PARP, two hallmarks of apoptosis, in β-TrCP1-depleted cells (Fig. 7c and Fig. S7C), suggesting that β-TrCP depletion sensitizes cancer cells to VM-26 by promoting apoptosis. Here, BTRC is linked to cancer.